source
- US patients skip half of new high-cost drugs as prices surge past $250KA new report from the Institute for Clinical and Economic Review and West Health finds that only about one-third of patients prescribed newly launched medicines actually fill them within 30 days, w…
- FDA approves GSK‑Ionis hepatitis B functional cure, Hibsago, targeting undetectable virus after six monthsThe FDA has approved bepirovirsen, an antisense oligonucleotide from GSK and Ionis, for chronic hepatitis B infection. It will be sold under the brand name Hibsago. The therapy is described as a f…